- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02663414
European Post-Market Study for Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction (Atlas-PMCF)
March 19, 2019 updated by: Moximed
European Post-Market, Prospective, Multi-Center, Single-Arm Study to Evaluate Symptom Relief in Subjects With Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction
The objective of this study is to collect post market data on safety and performance of the Atlas Knee System in patients with osteoarthritis (OA) of the medial knee compartment through a 24 months post-operative follow-up period.
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
The objective of this study is to collect post market data on safety and performance of the Atlas Knee System in patients with osteoarthritis (OA) of the medial knee compartment through a 24 months post-operative follow-up period.
This study is designed as a post-market, prospective, multicenter, single arm study.
The study population will consist of adult subjects older than 25 years of age, with a diagnosis of symptomatic and radiographic OA of the medial knee compartment.
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, older than 25 years of age;
- Have clinical symptoms in the study knee such as pain primarily localized to the medial aspect of the knee and generally exacerbated by weight bearing;
- Radiographic confirmation of osteoarthritis of the medial knee compartment without bony erosion and best assessed using a Rosenberg view X-ray;
Have failed at least 6 months of conservative therapy prior to surgery with continued OA pain. Prior conservative therapy is defined as treatment including at least one of the following (OARSI Recommendations)9:
- Lifestyle modification;
- Weight loss, if BMI >35;
- Pain relievers;
- Physical therapy;
- Assist devices (Canes, Orthotics, Braces, etc.);
- Intra-articular (IA) injections.
- Have active knee flexion ≥ 90⁰;
- Are able to give voluntary, written informed consent to participate in this clinical investigation.
- Are, in the opinion of the Clinical Investigator, able to understand this clinical investigation, cooperate with the investigational procedures, and are willing to return for all required post-treatment follow up visits.
Exclusion Criteria:
- Clinical symptoms and radiographic evidence of OA in the lateral compartment of the study knee;
- Clinical symptoms and radiographic evidence of OA in the patella-femoral compartment of the study knee;
- Tibio-femoral alignment of > 10⁰ of varus, or > 6° of valgus, as measured using anatomical axis on a long standing (Hip-Knee-Ankle) antero-posterior (AP) view X-ray, or tibio-femoral alignment of > 16⁰ of varus, or > 0⁰ of valgus as measured using mechanical axis on a long standing (Hip-Knee-Ankle) AP view X-ray;
- Previous joint modifying surgery in the study knee within 12 months prior to planned surgery date such as ligament reconstruction, meniscus repair, cartilage transplantation, and microfracture;
- Arthroscopic surgeries for joint lavage, medial meniscectomy, chondral debridement, and loose body removal if within 3 months prior to planned surgery date; Note: concomitant diagnostic arthroscopy including debridement during Atlas procedure is permitted.
- Active infection, sepsis, osteomyelitis or history of septic arthritis in any joint;
- Rheumatoid arthritis, other forms of inflammatory joint disease or autoimmune disorder;
- Excessive scarring of soft tissue structures of the medial knee;
- Hyperextension > 10⁰;
- Pathologic ligamentous instability (> 1 Medial collateral ligament injury or Lachman > 1 without hard stop) as assessed by the Investigator on physical examination;
- Severe deformities leading to impaired fixation or improper positioning of the implant;
- Paget's disease or metabolic disorders which may affect bone formation;
- Known or suspected diagnosis of Osteomalacia;
- Known or suspected diagnosis of Osteonecrosis;
- Known or suspected diagnosis of Osteoporosis;
- Rapid joint destruction, marked bone loss or bone resorption apparent on X-ray;
- Charcot's joint disease or other severe neurosensory deficits;
- Vascular insufficiency, muscular atrophy, neuromuscular disease;
- Immunologically suppressed or immunocompromised;
- History of systemic steroid treatment, medication use that affects bone metabolism (such as chemotherapy) within the previous 6 months, or radiotherapy within the previous 6 months;
- Any significant medical condition and other factors that the investigator feels would interfere with the participation and completion of the study;
- Pregnancy;
- Subjects who are currently enrolled in another clinical investigation that could affect the results of this investigation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atlas device
Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
|
The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain
Time Frame: Baseline and 24 month
|
Change from baseline to 24 months in pain measured by the Knee injury and Osteoarthritis outcome score (KOOS).
|
Baseline and 24 month
|
Function
Time Frame: Baseline and 24 month
|
Change from baseline to 24 months in patients functional outcome using the Knee injury and Osteoarthritis outcome score (KOOS).
|
Baseline and 24 month
|
Knee range of motion
Time Frame: Baseline and 24 month
|
No change from baseline to 24 months in Knee range of motion as measured by Investigator Orthopedic examination.
|
Baseline and 24 month
|
Monitoring of adverse events
Time Frame: Baseline to 24 month
|
Type, frequency, severity, and relatedness of adverse events will be assessed throughout the study.
|
Baseline to 24 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Function
Time Frame: Baseline and 24 month
|
Change from baseline to 24 months in patients functional outcome measured by the Knee Society score (KSS).
|
Baseline and 24 month
|
Activity
Time Frame: Baseline and 24 month
|
Change from baseline to 24 months in patients activity level using the University of California, Los Angeles (UCLA) activity scale.
|
Baseline and 24 month
|
Health outcome
Time Frame: Baseline and 24 month
|
Change from baseline to 24 months in patients health outcome using a health outcome measure (EQ-5D).
|
Baseline and 24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Tessa Yamut, Moximed
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Anticipated)
November 1, 2018
Study Completion (Anticipated)
November 1, 2018
Study Registration Dates
First Submitted
January 14, 2016
First Submitted That Met QC Criteria
January 21, 2016
First Posted (Estimate)
January 26, 2016
Study Record Updates
Last Update Posted (Actual)
March 21, 2019
Last Update Submitted That Met QC Criteria
March 19, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-102359
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis (OA) of the Medial Knee Compartment
-
UMC UtrechtCompletedMedial Compartment Osteoarthritis of the KneeNetherlands
-
University of Western Ontario, CanadaWithdrawnMedial Compartment Osteoarthritis of the KneeCanada
-
Fowler Kennedy Sport Medicine ClinicUnknown
-
University of IowaFoundation for Physical Medicine and Rehabilitation; Physiatric Association...CompletedMedial Compartment Knee OsteoarthritisUnited States
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Orient Europharma Co., Ltd.Completed
-
LG ChemCompletedOsteoarthritis (OA) of the KneePoland
-
Isra UniversityCompletedMedial Compartment Knee OsteoarthritisPakistan
-
Aesculap AGCompletedMedial Monocompartmental Osteoarthritis of the KneeGermany
-
AbbVieCompletedKnee Osteoarthritis | Medial Compartment Knee Osteoarthritis
Clinical Trials on Atlas Knee System
-
MoximedCompletedOsteoarthritis, KneeUnited States
-
Stryker NeurovascularUnknown
-
Sinomed Neurovita Technology Inc.RecruitingIntracranial AneurysmChina
-
Binx Health LimitedCompletedGonorrhea | Chlamydia TrachomatisUnited States
-
University Hospital, LilleJAPET MEDICAL DEVICECompletedChronic Low Back PainFrance
-
MarsiBionicsHospital General Universitario Gregorio Marañon; Hospital Infantil Universitario... and other collaboratorsRecruiting
-
Clinic of Phlebology and Laser Surgery, Chelyabinsk...RecruitingSubluxation and Dislocation of C0/C1 Cervical VertebraeRussian Federation
-
MarsiBionicsUniversidad de Zaragoza; Hospital Miguel Servet; ATADES; Spanish National Research... and other collaboratorsCompleted
-
University of CalgaryCompleted